Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Amyloid Fibrils

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...

The Proteasome

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Signal amplification using Ab-AuNPs integrated with LDI-MS analysis for diabetes screening in urine and saliva.

Lab on a chip·2025

Same author

Production and Purification of Recombinant SUMOylation Enzymes and SUMO Proteins.

Methods in molecular biology (Clifton, N.J.)·2025

Same author

Targeting SUMOylation Triggers IFN-β-dependent Activation of Patient and Allogenic NK Cells in Preclinical Models of Acute Myeloid Leukemia.

Molecular cancer therapeutics·2025

Same author

Facile fabrication of the immuno-MALDI-MS chip for the enrichment of abused drug in human urine integrated with MALDI-MS analysis.

Analytica chimica acta·2024

Same author

Generation of non-genetically modified, CAR-like, NK cells.

Journal for immunotherapy of cancer·2024

Same author

Region-Specific Phosphorylation Determines Neuroligin-3 Localization to Excitatory Versus Inhibitory Synapses.

Biological psychiatry·2023

Search research articles

Related Experiment Video

Updated: May 31, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Sumoylation inhibits alpha-synuclein aggregation and toxicity.

Petranka Krumova¹, Erik Meulmeester, Manuel Garrido

¹Department of Neurology and 2 Department of Biochemistry I, University of Göttingen, 37073 Göttingen, Germany.

The Journal of Cell Biology

|July 13, 2011

Summary

Small ubiquitin-related modifier (SUMO) attachment to proteins, or sumoylation, enhances protein solubility. This study shows sumoylation prevents aggregation of alpha-synuclein, a protein linked to Parkinson's disease.

More Related Videos

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Related Experiment Videos

Last Updated: May 31, 2026

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Isolating Potentiated Hsp104 Variants Using Yeast Proteinopathy Models

Published on: November 11, 2014

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

Area of Science:

Biochemistry
Cell Biology
Neuroscience

Background:

Posttranslational modification by small ubiquitin-related modifier (SUMO) impacts protein function.
Sumoylation is increasingly recognized for its role in maintaining protein solubility.
Alpha-synuclein aggregation is central to Parkinson's disease pathogenesis.

Purpose of the Study:

To investigate the role of sumoylation in the aggregation of alpha-synuclein.
To determine if sumoylation affects alpha-synuclein solubility and aggregation kinetics.
To assess the in vivo and cellular consequences of impaired alpha-synuclein sumoylation.

Main Methods:

Purified alpha-synuclein aggregation assays comparing unmodified and sumoylated forms.
Mapping of SUMO acceptor sites in alpha-synuclein.
Site-directed mutagenesis of identified SUMOylation sites (K96R, K102R).
Cell-based assays and in vivo studies using dopaminergic neurons.

Main Results:

Unmodified alpha-synuclein formed fibrils, while sumoylated alpha-synuclein remained soluble.
Even 10% sumoylated alpha-synuclein significantly delayed aggregation in vitro.
Mutating SUMOylation sites (K96R, K102R) impaired sumoylation, increasing aggregation and cytotoxicity in cells and in vivo.
The double mutant showed increased cytotoxicity in dopaminergic neurons.

Conclusions:

Sumoylation promotes protein solubility and inhibits the aggregation of alpha-synuclein.
Impaired sumoylation of alpha-synuclein contributes to its aggregation and associated cytotoxicity.
Defects in sumoylation may play a role in the pathogenesis of aggregation-induced diseases like Parkinson's.